NKGen Announces Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
SANTA ANA, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapeutics, today announced an upcoming poster presentation by its parent company, NKMax Co., Ltd., on preclinical and clinical data from a Phase I/IIa study of SNK01 in combination with cytotoxic chemotherapy in non-small cell lung cancer, at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held at the McCormick Place Convention Center in Chicago, Illinois from June 2-6, 2023.
About NKGen Biotech
Continental Breakfast Served
5 Good Reasons for a Single Pane of Glass
Securing Critical Operationâ€¦.Shedding Light on OT and Cybersecurity Risks